Atlas Trials

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Clinical trial NCT03507166 · COMPLETED

Trial details

NCT number
NCT03507166
Sponsor
RemeGen Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial CarcinomaAdvanced Cancer
Start date
2017-12-28
Primary completion
2018-10-29
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.